Swerdlow N R, Zisook D, Taaid N
Department of Psychiatry, UCSD School of Medicine, La Jolla 92093-0804.
Psychopharmacology (Berl). 1994 May;114(4):675-8. doi: 10.1007/BF02245001.
Seroquel (ICI 204,636) is a mixed D2/5HT2 antagonist with a preclinical profile suggestive of potential antipsychotic efficacy. We compared seroquel to clozapine in an animal model of sensorimotor gating deficits in shizophrenic patients. Like schizophrenic patients, rats treated with apomophrine (APO) exhibit deficits in prepulse inhibition (PPI) of acoustic startle. The ability of antipsychotics to restore PPI in APO-treated rats correlates (Rs = 0.991) with their clinical potency. Seroquel and clozapine both restore PPI in APO-treated rats. Seroquel's restoration of PPI in apomorphine-treated rats follows simple monotonic ascending dose-response properties, and is not accompanied by consistent changes in startle reflex amplitude. Seroquel's profile in this PPI model mimics that of other antipsychotics.
思瑞康(ICI 204,636)是一种兼具D2/5HT2拮抗作用的药物,其临床前研究资料提示它可能具有抗精神病疗效。我们在精神分裂症患者感觉运动门控缺陷的动物模型中,将思瑞康与氯氮平进行了比较。与精神分裂症患者一样,用阿扑吗啡(APO)治疗的大鼠在听觉惊吓的前脉冲抑制(PPI)方面表现出缺陷。抗精神病药物在APO治疗的大鼠中恢复PPI的能力与其临床效力相关(Rs = 0.991)。思瑞康和氯氮平都能在APO治疗的大鼠中恢复PPI。思瑞康在阿扑吗啡治疗的大鼠中恢复PPI呈现简单的单调递增剂量反应特性,且惊吓反射幅度无一致变化。思瑞康在这个PPI模型中的表现与其他抗精神病药物相似。